Abstrait

The study of correlation between neoadjuvant chemotherapy and the expression of VEGF, HIF-1? and MVD in breast cancer

Tian Ruihua, Li Yongqiang, Zheng Zongzhu

Objective: To explore the influence of neoadjuvant chemotherapy on expression of VEGF, HIF-1α and MVD in breast cancer tissue by detection before and after neoadjuvant chemotherapy and to analyse the correlation between the changes of these biological factors and the curative effect of chemotherapy.

Methods: Fifty female patients diagnosed as IIB-IIIC stage breast infiltrating ductal carcinoma in our hospital from September 2013 to September 2014 were treated with CET chemotherapy for 4-6 cycles, and also in surgical therapy to evaluate the efficacy of neoadjuvant chemotherapy. The expression of VEGF, HIF-1α, and MVD in core-needle biopsy specimens and postoperative specimens were detected by immunohistochemical method before and after neoadjuvant chemotherapy. SPSS13.0 software was used for statistical analysis.

Results: The MVD value of breast cancer tissue before chemotherapy was 32.17 ± 0.51, while 25.43 ± 0.68 after chemotherapy with the statistically significant difference (P<0.05). The effective rate of neoadjuvant chemotherapy was 95.23% in VEGF-negative group before chemotherapy, which was significantly higher than that in positive expression group (62.07%, P<0.05). The effective rate was 80.00% in HIF-1α-negative group, which was higher than that in the positive group (74.29%), there was no significant difference (P>0.05). Before chemotherapy, MVD value of the effective group was 31.62 ± 1.10, while chemotherapy ineffective group was 33.19 ± 0.88 without statistically significant difference (P>0.05).

Conclusions: 1. Neoadjuvant chemotherapy can significantly reduce the expression of VEGF and HIF-1α, and also the MVD value in breast cancer tissue. 2. The effective rate of neoadjuvant chemotherapy in VEGF-negative group was significantly higher than the positive group, suggesting that VEGF can be used as a predictor of neoadjuvant chemotherapy. 3. HIF-1α and MVD cannot be used as predictors of neoadjuvant chemotherapy.